|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ch. 26
|
|
2002 LAWS OF MARYLAND
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) ADDED TO SCHEDULE V BY THE DEPARTMENT UNDER § 5-202(B) OF
THIS TITLE; OR
(3) DESIGNATED AS A SCHEDULE V CONTROLLED DANGEROUS
SUBSTANCE BY THE FEDERAL GOVERNMENT UNLESS THE DEPARTMENT OBJECTS
UNDER § 5-202(F) OF THIS TITLE.
(B) CORE SUBSTANCES.
A SUBSTANCE IS LISTED IN SCHEDULE V IF THE SUBSTANCE INCLUDES A
COMPOUND, MIXTURE, OR PREPARATION THAT CONTAINS THE FOLLOWING
QUANTITIES OF NARCOTIC DRUGS OR THEIR SALTS:
(1) (I) NOT MORE THAN 200 MILLIGRAMS OF CODEINE PER 100
MILLILITERS OR PER 100 GRAMS;
(II) NOT MORE THAN 100 MILLIGRAMS OF DIHYDROCODEINE PER
100 MILLILITERS OR PER 100 GRAMS;
(III) NOT MORE THAN 50 MILLIGRAMS OF ETHYLMORPHINE PER 100
MILLILITERS OR PER 100 GRAMS;
(IV) NOT MORE THAN 2.5 MILLIGRAMS OF DIPHENOXYLATE AND
NOT LESS THAN 25 MICROGRAMS OF ATROPINE SULFATE PER DOSAGE UNIT; OR
(V) UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE, OR
UNLESS LISTED IN ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR
PREPARATION CONTAINING BUPRENORPHINE OR ITS SALT; AND
(2) NONNARCOTIC ACTIVE MEDICINAL INGREDIENTS IN SUFFICIENT
PROPORTION TO CONFER ON THE COMPOUND, MIXTURE, OR PREPARATION
VALUABLE MEDICINAL QUALITIES OTHER THAN THOSE POSSESSED BY THE
NARCOTIC DRUG ALONE.
(C) REQUIRED FACTORS FOR ADDING SUBSTANCE.
THE DEPARTMENT MAY NOT ADD A SUBSTANCE TO SCHEDULE V UNDER § 5-202
OF THIS SUBTITLE UNLESS THE DEPARTMENT FINDS:
(1) THE SUBSTANCE HAS A LOW POTENTIAL FOR ABUSE RELATIVE TO
THE SUBSTANCES LISTED IN SCHEDULE IV;
(2) THE SUBSTANCE HAS CURRENTLY ACCEPTED MEDICAL USE IN THE
UNITED STATES; AND
(3) ABUSE OF THE SUBSTANCE MAY LEAD TO LIMITED PHYSICAL
DEPENDENCE OR PSYCHOLOGICAL DEPENDENCE LIABILITY RELATIVE TO THE
SUBSTANCES LISTED IN SCHEDULE IV.
REVISOR'S NOTE: Subsection (a) of this section is new language added for
clarity and consistency.
Subsections (b) and (c) of this section are new language derived without
substantive change from former Art. 27, § 279(e).
|
|
|
|
|
|
|
|
|
|
- 416 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
